Abstract: Compositions and methods diagnose and/or treat chronic kidney disease (CKD) using one or more feline circulating proteins as markers for early-stage CKD. A method of diagnosing chronic kidney disease (CKD) in a feline can include measuring an amount of each of at least one circulating protein from the feline. The at least one circulating protein is one or more of adiponectin (ADIPOQ), cathelicidin (CAMP), kinesin-like protein (KIF12), plasma retinol-binding protein (RBP4), Ig-like domain-containing protein (ZKSCAN1), coagulation factor X (F10), fibronectin (FN1) and mixtures thereof. The method also includes performing comparison of the amount of each of the at least one circulating protein from the feline to a corresponding predetermined value or a corresponding predetermined range. The method also includes diagnosing the feline as having early-stage CKD or not having early-stage CKD, based on the comparison.

Abstract: A method for determining whether a subject has an impaired blood-brain barrier (BBB) or is at risk of developing an impaired blood-brain barrier (BBB) comprising determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the one or more biomarkers comprise serum amyloid A (SAA).

Abstract: Biomarkers for predicting weight loss The present invention provides a method for predicting the degree of weight loss attainable by applying one or more dietary interventions to a subject, said method comprising; determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the one or more biomarkers include vitamin K-dependent protein C.

Abstract: A method for predicting the degree of weight loss in a female subject attainable by applying one or more dietary interventions to a subject, said method comprising; determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the biomarkers are selected from gelsolin, apolipoprotein B-100, plasma kallikrein, protein Z-dependent protease inhibitor and plasma serine protease inhibitor.

Abstract: A method for predicting the degree of weight loss in male subject attainable by applying one or more dietary interventions to a subject, said method comprising determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the biomarkers are selected from sex hormone-binding globulin, beta-2-microglobulin and serum paraoxonase/arylesterase.